Skip to main content
. 2022 Oct 30;34(5):460–482. doi: 10.21147/j.issn.1000-9604.2022.05.07

Figure 2.

Figure 2

Current myeloid checkpoints in cancer immunotherapy. Ligands and elementary structures of CD47, SLAMF7, PD-1, LILRB1, LILRB2, LILRB4, Siglec-1, Siglec-9, Siglec-10, Siglec-15, TREM2, NRP1 and Clever1 are shown in this figure. PD-1, programmed cell death 1; LILRB, leukocyte immunoglobulin-like receptor B; Siglec, sialic acid-binding immunoglobulin-type lectin; TREM2, triggering receptor expressed on myeloid cells 2; NRP1, neuropilin-1; Clever1, commonlymphatic endothelial and vascular endothelial receptor-1.